Basic Information
Kyma Therapeutics will advance programs targeting immunomodulatory targets identified by Pyxis, developing new targets for antibody cancer and autoimmune diseases.
Kyma Therapeutics
Massachusetts,United States of America
15~50 people
May 25, 2021
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios